Cost-utility analysis of dupilumab vs omalizumab in the treatment of severe asthma

XU Nuo-ming, JIANG Xin-yue, HE Xiao-ning

PDF(1295 KB)
PDF(1295 KB)
Chinese Journal of New Drugs ›› 2025, Vol. 34 ›› Issue (19) : 2109-2116. DOI: 10.20251/j.cnki.1003-3734.2025.19.013

Cost-utility analysis of dupilumab vs omalizumab in the treatment of severe asthma

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2025, 34(19): 2109-2116 https://doi.org/10.20251/j.cnki.1003-3734.2025.19.013

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(1295 KB)

Accesses

Citation

Detail
Sections
Recommended
Total:
Copyright © Chinese Journal of New Drugs, All Rights Reserved.
Tel: 010-52722697 | 010-52723707
　 Powered by Beijing Magtech Co., Ltd.

/

〈 〉